Profil
Eric has been a distinguished medicinal chemist, company founder and senior executive since the early 1970s.
He was head of medicinal chemistry at Squibb and Bristol Myers Squibb in Princeton, where he worked for 18 years.
In 1992, he became Vice President of Research and Director of Chemistry at Affymax in Palo Alto, and had that role until the company was sold to Glaxo in 1995.
In 1996, he became scientific co-founder, President and Chief Scientific Officer of Versicor (later Vicuron Pharmaceuticals, which was acquired by Pfizer in 2005).
In 1998 he participated in the early stages of Sunesis Pharmaceuticals (NASDAQ: SNSS) and was Senior Vice President of Research until late 2002.
He is an accepted authority on combinatorial chemistry, medicinal chemistry, and creating drugs through enzyme inhibition.
Eric has authored more than 200 scientific manuscripts and U.S.
patents, and portions of 3 books, including editing a comprehensive book on combinatorial chemistry.
He is the senior author of two manuscripts which during 1994-1996 were the most frequently cited chemistry papers in the world.
He is on the Scientific Advisory Boards of the Cystic Fibrosis Foundation and the Organization for One World Health, as well as several biotechnology companies.
He serves on the Editorial Advisory Board of five scientific journals.
In 1997 he was elected a Fellow of the American Association for the Advancement of Science (AAAS).
He received his Ph.D.
and M.S.
in medicinal chemistry from the University of Wisconsin in Madison and conducted post-doctoral work at Yale University.
He joined Skyline in 2002.
Like John, he is a lifelong Yankee fan, but is old enough to have attended Woodstock, the Beatles concert at Shea Stadium in 1965, and the 1968 Democratic Convention in Chicago.
Postes actifs de Eric M. Gordon
| Sociétés | Poste | Début |
|---|---|---|
Skyline Management LLC
Skyline Management LLC Investment ManagersFinance Skyline Management invests in companies located in the United States. The firm focuses on companies operating in the fields of healthcare market, including biotechnology, therapeutics, medical devices, consumables and equipment for life sciences research and healthcare information technology. It participates in financing for early stage and later stage transactions with an investment size between USD 15 and 25 million. | Private Equity Investor | 01/01/2002 |
Arixa Pharmaceuticals, Inc.
Arixa Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops oral antibiotics for resistant gram-negative infections | Fondateur | 01/01/2016 |
Anciens postes connus de Eric M. Gordon
| Sociétés | Poste | Fin |
|---|---|---|
| TETRAPHASE PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 23/10/2012 |
Targanta Therapeutics Corp.
Targanta Therapeutics Corp. BiotechnologyHealth Technology Discovers and develops novel antibacterial pro drugs | Directeur/Membre du Conseil | 26/02/2009 |
| VIRACTA THERAPEUTICS, INC. | Corporate Officer/Principal | 31/12/2001 |
Vicuron Pharmaceuticals LLC
Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Fondateur | 31/12/1997 |
Affymax Research Institute
Affymax Research Institute Miscellaneous Commercial ServicesCommercial Services Researches and develops pharmaceutical products | Corporate Officer/Principal | 31/12/1995 |
Formation de Eric M. Gordon
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 10 |
|---|---|
Vicuron Pharmaceuticals LLC
Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Sunesis Pharmaceuticals, Inc.
Sunesis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops oncology therapeutics for treatment of solid and hematologic cancers | Health Technology |
Tetraphase Pharmaceuticals, Inc.
Tetraphase Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops novel antibiotics | Health Technology |
Targanta Therapeutics Corp.
Targanta Therapeutics Corp. BiotechnologyHealth Technology Discovers and develops novel antibacterial pro drugs | Health Technology |
Affymax Research Institute
Affymax Research Institute Miscellaneous Commercial ServicesCommercial Services Researches and develops pharmaceutical products | Commercial Services |
Skyline Management LLC
Skyline Management LLC Investment ManagersFinance Skyline Management invests in companies located in the United States. The firm focuses on companies operating in the fields of healthcare market, including biotechnology, therapeutics, medical devices, consumables and equipment for life sciences research and healthcare information technology. It participates in financing for early stage and later stage transactions with an investment size between USD 15 and 25 million. | Finance |
Squibb Corp.
Squibb Corp. Pharmaceuticals: MajorHealth Technology Drug and personal care products | Health Technology |
University of Wisconsin
University of Wisconsin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Limulus Management Co. LLC
Limulus Management Co. LLC Investment ManagersFinance Limulus Management Co LLC invests in healthcare/life science companies located in the US. The firm focuses on companies with intellectual property positions and growth potential. It targets companies operating in the fields of biopharmaceutical technology and life sciences information. It provides financing for early stage capital requirements with an investment size ranging from $4 to $8 million. | Finance |
Arixa Pharmaceuticals, Inc.
Arixa Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops oral antibiotics for resistant gram-negative infections | Health Technology |
















